Diabetic Neuropathy Market Size & Share, by Disorder (Peripheral, Autonomic, Proximal, Focal Neuropathy); Treatment (Drugs, Transcutaneous Electrical Nerve Stimulation (TENS)); End-user (Hospitals & Clinics, Retail Pharmacies, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4526
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Companies Dominating the Diabetic Neuropathy market

    • Hoffmann-La Roche Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • Eli Lilly and Company
    • Johnson & Johnson Services, Inc.
    • GlaxoSmithKline plc
    • Lupin Limited
    • Glenmark Pharmaceuticals Limited
    • Assertio Holdings, Inc.
    • Astellas Pharma US, Inc.
    • Pfizer Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • DyAnsys, Inc. received US Food and Drug Administration (FDA) for first relief, a PENS (Percutaneous Electrical Neurostimulation) that can be used to treat the pain of diabetic neuropathy.

  •  Medtronic plc declared its FDA approval for Intellis, a rechargeable neurostimulator, and Vanta, a recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy.


Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4526
  • Published Date: Feb 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing cases of diabetes and a rising population are major factors driving the growth of the diabetic neuropathy market.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2033.

High cost of treatment and undiagnosed cases are the challenges affecting the market growth

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Hoffmann-La Roche Ltd, Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Assertio Holdings, Inc., Astellas Pharma Inc., and Pfizer Inc.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disorder, treatment, end-user, and by region.

The peripheral Neurotherapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying